N6AMT1

Across TCGA pan-cancer cohorts, N6AMT1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated N6AMT1 data layer compared with 20 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher N6AMT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated N6AMT1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where N6AMT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.459	0.822	.012	16	view →
PDAC	OS	Median	II,III,IV	0.373	0.596	.023	5	view →
UCEC	DFS	Median	III,IV	0.460	0.889	.044	4	view →
HNSC	DFS	Quartile	IV	1.000	0.802	.048	2	view →
GBM	OS	Tertile	All	0.792	0.935	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

N6AMT1–CCRCC (DFS)

Open the CCRCC breakdown →